Yuyu Pharmaceutical presented a poster study for YP-P10, its new dry eye syndrome treatment, during the 2022 ARVO (Association for Research in Vision and Ophthalmology) conference.

ARVO, established in 1928, is the world's largest ophthalmology society and has 12,000 research members from over 75 countries. The 2022 ARVO conference was held in Denver, Col., from Sunday to Wednesday.

YP-P10 is a new biopharmaceutical using synthetic peptides, aiming to relieve signs and symptoms of dry eye syndrome caused by inflammation by administering the treatment twice a day.

According to preclinical trial results unveiled at the conference, Yuyu confirmed that the candidate had an excellent anti-inflammatory mechanism and corneal epithelial cell healing effect compared to existing drugs.

"The YP-P10 research result announced at the ARVO conference is part of phase 2 clinical trial conducted by the company after receiving U.S. Food and Drug Administration approval in April," Yuyu Pharmaceutical CEO Robert Yu said. "The company plans to administer the first drug to patients within the year's first half."

According to the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, the global dry eye syndrome market, worth $3.9 billion in 2018, will reach $5.6 billion by 2026, growing at 6.14 percent per year.